ASX - By Stock
|
ACR |
Re:
Ann: Activities Statement and Appendix 4C
|
|
parfait
|
7 |
2.7K |
5 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
7
|
2.7K
|
5
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux's seventh generic dossier accepted by FDA for review
|
|
parfait
|
8 |
3.5K |
9 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
8
|
3.5K
|
9
|
|
ASX - By Stock
|
ACR |
Re:
News: ACR Acrux Receives FDA Approval For Generic Version Of Aczone® Gel, 5% (Dapsone Gel 5%)
|
|
parfait
|
18 |
6.6K |
1 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
18
|
6.6K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Quarterly Activities / Appendix 4C Cashflow Report
|
|
parfait
|
8 |
2.8K |
3 |
30/01/23 |
30/01/23 |
ASX - By Stock
|
8
|
2.8K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Gedeon Richter buyout Lenzetto Royalties for EUR4.1million
|
|
parfait
|
13 |
4.7K |
2 |
23/01/23 |
23/01/23 |
ASX - By Stock
|
13
|
4.7K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Gedeon Richter buyout Lenzetto Royalties for EUR4.1million
|
|
parfait
|
13 |
4.7K |
2 |
23/01/23 |
23/01/23 |
ASX - By Stock
|
13
|
4.7K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Eficonazole and other approved things
|
|
parfait
|
18 |
5.7K |
3 |
11/01/23 |
11/01/23 |
ASX - By Stock
|
18
|
5.7K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Chairman and CEO address to AGM
|
|
parfait
|
14 |
3.5K |
0 |
23/11/22 |
23/11/22 |
ASX - By Stock
|
14
|
3.5K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Chairman and CEO address to AGM
|
|
parfait
|
14 |
3.5K |
1 |
23/11/22 |
23/11/22 |
ASX - By Stock
|
14
|
3.5K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
parfait
|
5 |
1.6K |
1 |
28/10/22 |
28/10/22 |
ASX - By Stock
|
5
|
1.6K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Appendix 4E and FY22 Annual Report
|
|
parfait
|
20 |
6.0K |
2 |
26/08/22 |
26/08/22 |
ASX - By Stock
|
20
|
6.0K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
News: ACR Acrux Says Its Sixth Generic Application Accepted By U.S. FDA For Review
|
|
parfait
|
27 |
5.4K |
3 |
25/08/22 |
25/08/22 |
ASX - By Stock
|
27
|
5.4K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
News: ACR Acrux Says Its Sixth Generic Application Accepted By U.S. FDA For Review
|
|
parfait
|
27 |
5.4K |
0 |
25/08/22 |
25/08/22 |
ASX - By Stock
|
27
|
5.4K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
News: ACR Acrux Says Its Sixth Generic Application Accepted By U.S. FDA For Review
|
|
parfait
|
27 |
5.4K |
1 |
24/08/22 |
24/08/22 |
ASX - By Stock
|
27
|
5.4K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux announces commercial agreement with Padagis
|
|
parfait
|
14 |
5.0K |
1 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
14
|
5.0K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux announces commercial agreement with Padagis
|
|
parfait
|
14 |
5.0K |
2 |
20/06/22 |
20/06/22 |
ASX - By Stock
|
14
|
5.0K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux announces commercial agreement with Padagis
|
|
parfait
|
14 |
5.0K |
1 |
20/06/22 |
20/06/22 |
ASX - By Stock
|
14
|
5.0K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Appendix 4D, Half Year Accounts as at 31 December 2021
|
|
parfait
|
32 |
5.8K |
3 |
24/02/22 |
24/02/22 |
ASX - By Stock
|
32
|
5.8K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Appendix 4D, Half Year Accounts as at 31 December 2021
|
|
parfait
|
32 |
5.8K |
0 |
24/02/22 |
24/02/22 |
ASX - By Stock
|
32
|
5.8K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
Countdown to Cashflow Positive
|
|
parfait
|
88 |
27K |
3 |
18/02/22 |
18/02/22 |
ASX - By Stock
|
88
|
27K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux's fifth generic dossier accepted by FDA for review
|
|
parfait
|
22 |
5.6K |
3 |
17/09/21 |
17/09/21 |
ASX - By Stock
|
22
|
5.6K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux's fifth generic dossier accepted by FDA for review
|
|
parfait
|
22 |
5.6K |
5 |
13/09/21 |
13/09/21 |
ASX - By Stock
|
22
|
5.6K
|
5
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux receives third FDA ANDA approval
|
|
parfait
|
20 |
5.7K |
3 |
03/08/21 |
03/08/21 |
ASX - By Stock
|
20
|
5.7K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux receives third FDA ANDA approval
|
|
parfait
|
20 |
5.7K |
3 |
03/08/21 |
03/08/21 |
ASX - By Stock
|
20
|
5.7K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux receives third FDA ANDA approval
|
|
parfait
|
20 |
5.7K |
1 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
20
|
5.7K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux receives third FDA ANDA approval
|
|
parfait
|
20 |
5.7K |
2 |
28/07/21 |
28/07/21 |
ASX - By Stock
|
20
|
5.7K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux Receives FDA Approval - Generic Efinaconazole Solution
|
|
parfait
|
17 |
6.4K |
6 |
22/06/21 |
22/06/21 |
ASX - By Stock
|
17
|
6.4K
|
6
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Acrux's fourth generic dossier accepted by FDA for review
|
|
parfait
|
37 |
13K |
4 |
19/04/21 |
19/04/21 |
ASX - By Stock
|
37
|
13K
|
4
|
|
ASX - By Stock
|
ACR |
Re:
ACR - Efinaconazole
|
|
parfait
|
32 |
11K |
0 |
15/04/21 |
15/04/21 |
ASX - By Stock
|
32
|
11K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
ACR - Efinaconazole
|
|
parfait
|
32 |
11K |
2 |
15/04/21 |
15/04/21 |
ASX - By Stock
|
32
|
11K
|
2
|
|
ASX - By Stock
|
CLH |
Re:
Ann: Suspension from Official Quotation
|
|
parfait
|
59 |
504K |
0 |
18/02/20 |
18/02/20 |
ASX - By Stock
|
59
|
504K
|
0
|
|
ASX - By Stock
|
NAB |
Re:
when will it end
|
|
parfait
|
116 |
261K |
2 |
13/12/19 |
13/12/19 |
ASX - By Stock
|
116
|
261K
|
2
|
|
ASX - By Stock
|
PNC |
Re:
Ann: Pioneer signs Scheme Implementation Agreement with Carlyle
|
|
parfait
|
58 |
30K |
1 |
11/12/19 |
11/12/19 |
ASX - By Stock
|
58
|
30K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Presentation - Australian Microcap Investment Conference
|
|
parfait
|
8 |
10K |
3 |
20/11/19 |
20/11/19 |
ASX - By Stock
|
8
|
10K
|
3
|
|